Search
Filter Results
Displaying 671–680 of 829 for “retinal diseases”
-
Dec 20, 2012
Curing Blindness, Part 2: Dick’s Story
Stem-cell-based therapies – including those derived from a patient’s blood or skin – are among the many cutting-edge approaches to treatments the Foundation has funded for decades.
-
Feb 12, 2024
“The Future Holds Promise” on International Day of Women and Girls in Science
International Day of Women and Girls in Science is celebrated globally to recognize the critical role women play in science, technology, engineering, and mathematics. To honor this vital day, the Foundation is sharing the story of Dr. Esther Biswas-Fiss.
-
Dec 18, 2012
Curing Blindness, Part 1: Corey’s Story
How gene therapy restored some of a boy’s sight.
-
Nov 10, 2023
Eye on the Cure Podcast | Episode 56: Michael Voevodsky, MBA, CEO
Michael Voevodsky, MBA, CEO at MitoChem Therapeutics, talks to host Ben Shaberman about his company’s emerging, gene-agnostic treatment designed to boost mitochondrial function for preserving vision in people with retinitis pigmentosa, age-related macular degeneration, and other retinal conditions.
-
Apr 28, 2023
Eye on the Cure Podcast | Episode 45: Henry Klassen, MD, PhD
April 28, 2023. Henry Klassen, MD, PhD, co-founder of jCyte and clinical researcher at UC Irvine, talks to host Ben Shaberman about jCyte’s clinical trial results and future plans for developing its cell-based therapy for preserving vision caused by retinitis pigmentosa, Usher syndrome, and related retinal conditions.
-
Translational Research Acceleration Program Award
The Translational Research Acceleration Program awards will accelerate the movement of preclinical research toward an Investigational New Drug filing and into clinical trials to provide a robust and diverse pipeline of potential therapies to fight inherited retinal degenerations (IRD) and dry age-related macular degeneration.
-
Dec 21, 2018
Applied Genetic Technologies Corporation (AGTC), a leading developer of gene therapies, has reported the six-month follow-up data in all patients treated with its gene therapy for X-linked retinoschisis (XLRS) in its Phase I/II clinical trial.
-
Mar 19, 2012
When it comes to describing Eric Fulton, “gregarious” is a more-than-appropriate adjective for the husband and father of two who, fittingly, is also communications manager at the Bethesda-based Clark Construction Group. “It comes naturally to me,” he says of his ability to mix it up with people. “The cause makes it easier. But, otherwise, I’m pretty outgoing; I like to talk to people. It’s what I do.”
-
May 27, 2020
Lulie Gund: Beloved Philanthropist, Role Model and Confidant
Llura Gund, often referred to as Lulie, was known for her infectious kind smile and love of life.
-
Feb 9, 2024
The company plans to begin a Phase 2/3 clinical trial for the treatment during the first half of 2024.